Indications and uses
■ Temporarily relieves the minor aches and pains of muscles and joints associated with: ■ arthritis ■ strains ■ bruises ■ sprains ■ backache
■ Temporarily relieves the minor aches and pains of muscles and joints associated with: ■ arthritis ■ strains ■ bruises ■ sprains ■ backache
Directions ■ Use only as directed ■ Adults and children 12 years of age and older apply to affected area not more than 3 to 4 times daily ■ Children under 12 years of age ask a doctor
Camphor 4% .……..…….............….. Topical Analgesic
Menthol 10% ...……......……….....… Topical Analgesic
Methyl Salicylate 30% .......….......… Topical Analgesic
■ Temporarily relieves the minor aches and pains of
muscles and joints associated with: ■ arthritis
■ strains ■ bruises ■ sprains ■ backache
For external use only
Do not use: ■ on wounds or damaged skin
■ with a heating pad ■ on a child under 12 years of
age with arthritis like conditions
Directions
■ Use only as directed
■ Adults and children 12 years of age and older apply
to affected area not more than 3 to 4 times daily
■ Children under 12 years of age ask a doctor
Inactive ingredients
water, carbomer, disodium edta, glyceryl stearate se,
lanolin, polysorbate 80, stearic acid, triethanolamine,
potassium hydroxide
Questions? Call 1-866-923-4914
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 283083 | camphor 4 % / menthol 10 % / methyl salicylate 30 % Topical Cream | PSN | 2 |
| 283083 | camphor 40 MG/ML / menthol 100 MG/ML / methyl salicylate 300 MG/ML Topical Cream | SCD | 2 |
| 283083 | camphor 4 % / menthol 10 % / methyl salicylate 30 % Topical Cream | SY | 2 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| dea2eded-d1e7-46bb-9a3d-f8dc20de6277 | Product name | 1 | 20190408 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 24488-001-22 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-c795-621f-e053-dbdaa90a74ad | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 24488-001-22 | Pain Relieving Ultra Strength | 1 in 1 CARTON | CREAM | 1 | 2 | |
| 24488-001-22 | Pain Relieving Ultra Strength | 113 g in 1 TUBE | CREAM | 113 | 2 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CAMPHOR (SYNTHETIC) | ACTIVE INGREDIENT | 5TJD82A1ET | 2 | |
| Menthol | ACTIVE INGREDIENT | L7T10EIP3A | 2 | |
| Methyl Salicylate | ACTIVE INGREDIENT | LAV5U5022Y | 2 | |
| CAMPHOR (SYNTHETIC) | ACTIVE MOIETY | 5TJD82A1ET | 2 | |
| Menthol | ACTIVE MOIETY | L7T10EIP3A | 2 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 2 | |
| Carbomer Homopolymer Type C | INACTIVE INGREDIENT | 4Q93RCW27E | 2 | |
| Edetate Disodium | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| Glyceryl Monostearate | INACTIVE INGREDIENT | 230OU9XXE4 | 2 | |
| Lanolin | INACTIVE INGREDIENT | 7EV65EAW6H | 2 | |
| Polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 2 | |
| Potassium Hydroxide | INACTIVE INGREDIENT | WZH3C48M4T | 2 | |
| Stearic Acid | INACTIVE INGREDIENT | 4ELV7Z65AP | 2 | |
| Trolamine | INACTIVE INGREDIENT | 9O3K93S3TK | 2 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 24488-001 | 24488-001-22 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CAMPHOR (SYNTHETIC) | 5TJD82A1ET | ACTIB |
| Menthol | L7T10EIP3A | ACTIB |
| Methyl Salicylate | LAV5U5022Y | ACTIB |
| Water | 059QF0KO0R | IACT |
| Carbomer Homopolymer Type C | 4Q93RCW27E | IACT |
| Edetate Disodium | 7FLD91C86K | IACT |
| Glyceryl Monostearate | 230OU9XXE4 | IACT |
| Lanolin | 7EV65EAW6H | IACT |
| Polysorbate 80 | 6OZP39ZG8H | IACT |
| Stearic Acid | 4ELV7Z65AP | IACT |
| Trolamine | 9O3K93S3TK | IACT |
| Potassium Hydroxide | WZH3C48M4T | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY, METERED / NASAL | 4 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 6 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | EMULSION / OPHTHALMIC | 0.3 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / NASAL | 100 mg/100ml | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / INTRAVENOUS | 900 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | EMULSION / ORAL | NA | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 1 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | DROPS / OPHTHALMIC | 0.05 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRALESIONAL | 0.05 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 19 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET / ORAL | 33.34 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | OINTMENT / TOPICAL | 1 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / ORAL | 907 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRAMUSCULAR | 4 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRASYNOVIAL | 4 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LIQUID / TOPICAL | 1 %w/w | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / VAGINAL | 4 %w/w | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / OPHTHALMIC | 8 mg | ||
| Potassium Hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | SOLUTION / TOPICAL | 14.02 %w/w | ||
| Lanolin | LANOLIN | 7EV65EAW6H | EMULSION / TOPICAL | 0.25 %w/w | ||
| Trolamine | TROLAMINE | 9O3K93S3TK | GEL, METERED / TRANSDERMAL | 14 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, CHEWABLE / ORAL | 84 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAVENOUS | 7 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | AEROSOL, FOAM / TOPICAL | 0.98 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / ORAL | 30 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | AEROSOL, FOAM / TOPICAL | 3.27 %w/w | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, DELAYED RELEASE / ORAL | 23 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | POWDER / ORAL | 66 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | GEL / TOPICAL | 12 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, DELAYED RELEASE / ORAL | 6 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, ORALLY DISINTEGRATING / ORAL | 3 mg | ||
| Lanolin | LANOLIN | 7EV65EAW6H | OINTMENT / RECTAL | 105 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, COATED / ORAL | 0.04 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / OPHTHALMIC | 4 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / AURICULAR (OTIC) | 0.1 %w/v | ||
| Potassium Hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE / ORAL | 172 mg | ||
| Trolamine | TROLAMINE | 9O3K93S3TK | AEROSOL, METERED / RECTAL | ADJ PH | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRASYNOVIAL | 0.2 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | LOTION / TOPICAL | 15 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, DELAYED RELEASE / ORAL | 100 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | PASTE / ORAL | 28 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.01 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | CREAM / VAGINAL | 3 mg | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | CAPSULE / ORAL | 90 mg | ||
| Potassium Hydroxide | POTASSIUM HYDROXIDE | WZH3C48M4T | CREAM / TOPICAL | 0.5 %w/w | ||
| Trolamine | TROLAMINE | 9O3K93S3TK | DROPS / NASAL | NA | ||
| Trolamine | TROLAMINE | 9O3K93S3TK | SOLUTION / TOPICAL | NA | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | AEROSOL, FOAM / RECTAL | 2 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE, EXTENDED RELEASE / ORAL | 32.4 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | DROPS / AURICULAR (OTIC) | 0.05 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SHAMPOO, SUSPENSION / TOPICAL | 1 %w/w | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | EMULSION / ORAL | NA | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / OPHTHALMIC | 1 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE, DELAYED RELEASE / ORAL | 15 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9eeb2e24-edb9-446f-93d6-aa1613ccd39a | 08cdeefb-33b7-4991-9a09-0e299be9d950 | 2010-03-31 | Warnings | 9eeb2e24-edb9-446f-93d6-aa1613ccd39a 08cdeefb-33b7-4991-9a09-0e299be9d950 |
Adverse event summaries are temporarily unavailable. Other product information remains available.